The effects of cyclic peptide [R4W4] in combination with first-line therapy on the survival of Mycobacterium avium
Frontiers in Cellular and Infection Microbiology · 2025
DOI: 10.3389/fcimb.2025.1547376 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Melissa Kelley und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, United States. Hauptthemen laut MEDLINE: Mycobacterium avium, Peptides, Cyclic, Anti-Bacterial Agents, Microbial Viability. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Background
Mycobacterium avium ( M. avium ) is a nontuberculous mycobacterium (NTM) that can cause pulmonary and extrapulmonary infections mostly in immunocompromised individuals, such as those with HIV and diabetes. Traditionally, rifampicin (RIF) and azithromycin (AZ) have been used for a 12-month duration as first-line antibiotics against M. avium . Due to the increased multidrug resistance, novel ways, such as enhancement of macrophages response, are needed to provide adequate immune response required to clear M. avium infection. Methods and findings In this study, we aim to study the effects of using THP-1 cells, which are monocyte-like cells, to induce a macrophage response and control M. avium infection when used in combination with traditional treatments such as RIF and AZ in free and liposomal forms. Traditional treatments’ effects are studied when used alone and in combination therapy with cyclic peptide [R4W4] (liposomal encapsulated and liposomal combination). Colony-forming units (CFU) counts were assessed for all samples 3 hours, 4 days, and 8 days post-treatment. A significant reduction in the intracellular viability of M. avium was observed when THP-1 cells were treated with liposomal combination [R4W4]+RIF and liposomal combination [R4W4]+AZ compared to when treated with liposomal RIF or liposomal AZ alone, respectively.
Conclusion
Our findings show that liposomal combination [R4W4] is a promising adjuvant therapy to increase M. avium susceptibility to known antibiotics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, United States.
- Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, United States.
- Department of Pharmaceutics, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.
- Department of Biomedical Sciences, College of Osteopathic Medicine of the Pacific-Northwest, Western University of Health Sciences, Lebanon, OR, United States.
Förderung
- NHLBI NIH HHS
Zitieren
APA
Kelley, M., Sasaninia, K., Badaoui, A., Glassman, I., Abnousian, A., Rai, N., Tiwari, R. K., & Venketaraman, V. (2025). The effects of cyclic peptide [R4W4] in combination with first-line therapy on the survival of Mycobacterium avium. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1547376
Vancouver
Kelley M, Sasaninia K, Badaoui A, Glassman I, Abnousian A, Rai N, et al. The effects of cyclic peptide [R4W4] in combination with first-line therapy on the survival of Mycobacterium avium. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1547376
BibTeX
@article{Kelley2025,
author = {Kelley, Melissa and Sasaninia, Kayvan and Badaoui, Ali and Glassman, Ira and Abnousian, Arbi and Rai, Nadia and Tiwari, Rakesh K and Venketaraman, Vishwanath},
title = {The effects of cyclic peptide [R4W4] in combination with first-line therapy on the survival of Mycobacterium avium},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
doi = {10.3389/fcimb.2025.1547376}
}
EUVIMED